（编辑 任世碧） 证券日报网讯 7月29日晚间，恩华药业发布公告称，公司第七届董事会第三次会议审议通过了《公司 2025年半年度报告全文及摘要》《关于2024年限制性股票激励计划授予的限制性股票第一个解除限售期 解除限售条件成就的议案》。 ...

Core Viewpoint - Enhua Pharmaceutical reported continuous growth in its operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] Financial Performance - The company achieved an operating revenue of 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - The net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase year-on-year [1] R&D Investment - Enhua Pharmaceutical invested approximately 395 million yuan in research and development, representing a 23.97% increase compared to the previous year [2] - The company has over 70 ongoing research projects in the pipeline and holds the largest product line in the central nervous system drug sector in China [2] Innovative Drug Development - The company has 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - Collaborations include partnerships with San Sheng Pharmaceutical and Harvard Medical School for various drug development projects [3] Digital Healthcare Development - Enhua Pharmaceutical has established a digital healthcare platform since 2015, which includes online consultation and health services, with over 70,000 registered doctors and more than 2 million patient visits annually [4] - The company has developed several digital mental health products, including AI-based psychological risk screening systems and virtual reality tools [4] Expansion and Partnerships - The company operates 25 psychological clinics and has signed contracts with over 400 corporate clients, covering nearly 2 million individuals [5] - Enhua Pharmaceutical is actively pursuing overseas listing plans to expand financing channels and support business growth [5]

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, an increase of 11.38% year-on-year [1] - The basic earnings per share stood at 0.69 yuan [1] R&D Investment and Projects - The company has over 70 ongoing research projects with a research expenditure of 395 million yuan, reflecting a growth of 23.97% compared to the same period last year [2] - In the area of innovative drug development, there are currently 17 ongoing projects, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II trials [2] - The company is also engaged in 48 generic drug projects, with 1 project having received production approval and 5 projects currently under review for production [2]

Financial Performance - The company reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, showing a year-on-year growth of 11.38% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 699 million yuan, with a year-on-year increase of 10.33% [1] - The basic earnings per share were 0.69 yuan [1] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of 395 million yuan, which is a 23.97% increase compared to the same period last year [2] - In the field of innovative drug development, there are currently 17 innovative drug projects under research, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II clinical trials [2] - The company is conducting 48 projects in generic drug development, with 1 project having received production approval and 5 projects currently under review for production approval [2]

Group 1 - The company reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders reached 700 million yuan, with a year-on-year increase of 11.38% [1] - The basic earnings per share stood at 0.69 yuan [1]

Core Viewpoint - Enhua Pharmaceutical (002262.SZ) reported a revenue of 3.01 billion yuan for the first half of 2025, reflecting a year-on-year growth of 8.93% [1] - The net profit attributable to shareholders reached 700 million yuan, marking an increase of 11.38% year-on-year [1] - The net profit excluding non-recurring gains and losses was 699 million yuan, showing a year-on-year growth of 10.33% [1] - Basic earnings per share stood at 0.69 yuan [1]

截至发稿，恩华药业市值为233亿元。 每经头条（nbdtoutiao）——直击首例基孔肯雅热报告社区：下水井盖都加装纱网和胶带，已很难见到 一只蚊子！千人投入"防蚊战" （记者 胡玲） 每经AI快讯，恩华药业（SZ 002262，收盘价：22.93元）7月29日晚间发布公告称，公司第七届第三次 董事会会议于2025年7月29日在徐州市经济技术开发区龙湖西路31号恩华科技大厦20楼会议室召开。会 议审议了《公司2025年半年度报告全文及摘要》等文件。 2025年1至6月份，恩华药业的营业收入构成为：工业占比85.81%，医药商业占比13.08%，其他贸易及 劳务占比0.58%，其他业务占比0.52%。 ...

证券代码：002262 证券简称：恩华药业 公告编号：2025-046 江苏恩华药业股份有限公司 关于2024年限制性股票激励计划授予的限制性股票 第一个解除限售期解除限售条件成就的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 特别提示： 1、本次符合解除限售条件的激励对象共计750人，本次限制性股票解除限售数量为 226.4451万股，占公司目前总股本的0.2228%。 2、本次限制性股票解除限售尚需在相关部门办理解除限售手续，在上市流通前，公司将 发布相关提示性公告，敬请投资者注意。 江苏恩华药业股份有限公司(以下简称：公司)于2025年7月29日召开了第七届董事会第三 次会议、第七届监事会第三次会议，审议通过了《关于2024年限制性股票激励计划授予的限制 性股票第一个解除限售期解除限售条件成就的议案》。根据《上市公司股权激励管理办法》（以 下简称：《管理办法》）《江苏恩华药业股份有限公司2024年限制性股票激励计划（草案）》（以 下简称：《激励计划（草案）》）的相关规定，公司2024年限制性股票激励计划（以下简称：本 次激励计划）授予的限 ...

第一个解除限售期解除限售条件成就 证券代码：002262 公司简称：恩华药业 上海荣正企业咨询服务（集团）股份有限公司 关于 江苏恩华药业股份有限公司 2024 年限制性股票激励计划 以下词语如无特殊说明，在本文中具有如下含义： | 恩华药业、公 | 指 | 江苏恩华药业股份有限公司 | | --- | --- | --- | | 司 | | | | 本激励计划、 | 指 | 江苏恩华药业股份有限公司2024年限制性股票激励计划 | | 本计划 | | | | 限制性股票 | 指 | 公司根据本激励计划规定的条件和价格，授予激励对象一定数 | | | | 量的公司股票，该等股票设置一定期限的限售期，在达到本激 | | | | 励计划规定的解除限售条件后，方可解除限售流通 | | 激励对象 | 指 | 按照本激励计划规定，获得限制性股票的公司（含分公司及控 股子公司）任职的董事、高级管理人员、中层管理人员及核心 | | | | 骨干员工 | | 授予日 | 指 | 公司向激励对象授予限制性股票的日期，授予日必须为交易日 | | 授予价格 | 指 | 公司授予激励对象每一股限制性股票的价格 | | 有效期 | 指 ...